What is BacterioScan?
BacterioScan operates at the intersection of clinical diagnostics and antibiotic stewardship, offering the only FDA-cleared device specifically engineered for rapid UTI detection. By utilizing advanced light scattering technology, the platform delivers diagnostic results within a 30 to 180-minute window, boasting a sensitivity of 97.7% and a negative predictive value of 99.2%. This technological capability is essential for modern healthcare providers, as it enables the immediate identification of true-negative cases, thereby preventing the unnecessary prescription of antibiotics and reducing overall healthcare expenditures. The company's focus on speed, accuracy, and affordability addresses long-standing inefficiencies in traditional laboratory testing, establishing a new standard for point-of-care diagnostics in the clinical environment.
How much funding has BacterioScan raised?
BacterioScan has raised a total of $9.9M across 4 funding rounds:
Unspecified
$2.1M
Series A
$6M
Unspecified
$1.7M
Debt
$150K
Unspecified (2013): $2.1M, investors not publicly disclosed
Series A (2014): $6M led by Warson Capital Partners, BioGenerator, and Missouri Technology
Unspecified (2015): $1.7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in BacterioScan
Warson Capital Partners
Warson Capital Partners is a St. Louis-based firm specializing in capital sourcing, mergers and acquisitions, and financial restructuring for middle-market companies.
BioGenerator
BioGenerator is a St. Louis-based organization that fosters innovation by providing both venture capital investment and comprehensive startup support through its dedicated laboratory facilities.
Missouri Technology Corporation
The Missouri Technology Corporation is a public-private partnership focused on enhancing entrepreneurship and supporting high-tech development within the life sciences and technology sectors.
What's next for BacterioScan?
With the support of its recent strategic investment, BacterioScan is poised to accelerate its commercial expansion and deepen its penetration into the clinical diagnostic market. The company's forward-looking strategy centers on enhancing antibiotic stewardship programs across healthcare systems, a move that aligns with global efforts to combat antimicrobial resistance. By scaling its operational capacity and refining its diagnostic suite, BacterioScan is well-positioned to capitalize on the increasing demand for rapid, decentralized testing solutions. Future growth will likely focus on expanding the clinical utility of its light scattering platform, potentially addressing a broader range of infectious disease diagnostics while maintaining its commitment to high-precision, cost-effective patient care.
See full BacterioScan company page
